Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Avelumab [USAN:INN]
RN: 1537032-82-8


  • NCI: A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis. (NCI Thesaurus)
  • Targets programmed cell death protein-1 ligand; has antineoplastic activity.

Molecular Formula

  • C6374-H9898-N1694-O2010-S44 (non-glycosylated)

Classification Codes

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Treatment of Cancer
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Avelumab [USAN:INN]


  • Avelumab
  • Bavencio
  • Immunoglobulin G1-lambda1, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), homo sapiens monoclonal antibody
  • MSB-0010682
  • MSB-0010718C
  • MSB0010682
  • MSB0010718C

Registry Numbers

CAS Registry Number

  • 1537032-82-8


  • KXG2PJ551I

System Generated Number

  • 1537032828